The QualityStocks Daily Friday, June 3rd, 2022

Today's Top 3 Investment Newsletters

BioMedWire(POAI) $0.4600 +21.05%

CryptoCurrencyWire(GBOX) $2.5500 +20.28%

Broad Street(EVFM) $0.3980 +15.77%

The QualityStocks Daily Stock List

Galecto (GLTO)

QualityStocks, StreetInsider, MarketClub Analysis and MarketBeat reported earlier on Galecto (GLTO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Galecto Inc. (NASDAQ: GLTO) is a clinical-stage biotechnology firm that is focused on the development of molecules that treat inflammation, cancer and fibrosis, among other ailments.

The firm has its headquarters in Copenhagen, Denmark and was incorporated in 2011 by Hans T. Schambye, Tariq Sethi, Hakon Leffler and Ulf Nilsson. It operates in the healthcare sector under the biotech and pharma sub-industry and serves consumers across the globe.

The company builds on over a decade of research focused on the role of lysyl oxidase-like 2 (LOXL-2) and galectin-3 as well as the use of modulators of these proteins in the treatment of cancer and fibrosis-related ailments.

The enterprise’s product pipeline is made up of a selective oral galectin-3 inhibitor known as GB1211 that is undergoing phase 1/2a trials evaluating its effectiveness in treating fibrosis associated with non-alcoholic steatohepatitis and cancer; and a formulation dubbed GB2064 currently in its phase 1/2a trials evaluating its efficacy in treating myelofibrosis, which is a malignant illness of the bone marrow that diminishes its ability to produce blood cells. In addition to this, the enterprise also develops an inhaled galectin-3 inhibitor dubbed GB0139, which is undergoing phase 2 b clinical trials assessing its efficacy in treating serious fibrotic lung ailments, like idiopathic pulmonary fibrosis, which is a fatal progressive fibrotic illness of the lung.

The success of the firm’s GB0139 formulation will help meet clinically unmet needs that will benefit patients who suffer from severe fibrotic lung diseases. This is in addition to encouraging more investments into the firm, which will be good for the company’s growth.

Galecto (GLTO), closed Friday's trading session at $1.96, up 35.1724%, on 1,930,092 volume with 4,954 trades. The average volume for the last 3 months is 1.849M and the stock's 52-week low/high is $1.17/$16.41.

Hiru Corporation (HIRU)

OTCReporter, Mina Mar Marketing Group, Willy Wizard, Stockpalooza, CRWEWallStreet, BestOtc, CoolPennyStocks, CRWEFinance, DrStockPick, StockHotTips, PennyOmega, Penny Invest, PennyToBuck, HotOTC, StockEgg, CRWEPicks, BullRally, Stock Rich, OTCPicks, Epic Stock Picks, StockRockandRoll, Stocks Gone Wild, PennyStockLocks, Wise Alerts, Penny Stock 101, HEROSTOCKS, Micro Cap Momentum, QualityStocks, Topgun stockpicks, Penny stock Profitz, The Stock Psycho, Stocktwiter, Purely Penny Stocks, Stock Exploder, Bull Warrior Stocks, StocksAlarm, StockMister, Penny Stocks Pushers, SmarTrend Newsletters, Penny Picks, Greenbackers, Pumps and Dumps, Light Speed Stocks, PennyStockRumors.net, Wise Penny Stocks, BeatPennyStocks and Damn Good Penny Picks reported earlier on Hiru Corporation (HIRU), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Hiru Corporation (OTC: HIRU) is engaged in the production of Chinese herbs for China’s naturopathic industry.

The firm has its headquarters in Phoenix, Arizona and was incorporated in 1989. Prior to its name change in November 2008, the firm was known as Phoenix Restaurant Group Inc.

The company distributes and sells its pharmaceuticals, dietary and herbal supplements, beauty and health products and other healthcare products via regional distributors, as well as directly to pharmacies, clinics and hospitals in China.

The enterprise manufactures herbal supplements that contain ginseng and an additional 120 extracts which are also utilized in traditional Chinese medicine. It also provides consumers in the state of Arizona with bottled water and bagged ice. In addition, it is involved in the development, manufacture and commercialization of various veterinary products for the agricultural market in China via its Jiangxi Shuangshi AHP Co. subsidiary whose objective is to protect both human and animal health. The enterprise is focused on expanding its research and development and is planning to introduce veterinary solutions and drugs to the Chinese market via its subsidiary. To improve the health of livestock, the firm produces premixes, loose powders, feed additives, liquid disinfectants, oral liquids, injections, volume injections and other injectables.

The company is focused on meeting all of its consumers’ demands having recently appointed a new CEO. This appointment will help bring in a lot of investment opportunities as well as business into the firm, which are bound to have a positive effect on the company’s growth.

Hiru Corporation (HIRU), closed Friday's trading session at $0.0027, up 35%, on 68,500,746 volume with 174 trades. The average volume for the last 3 months is 68.501M and the stock's 52-week low/high is $0.0015/$0.022.

Blue Dolphin Energy Co. (BDCO)

MarketBeat, OTCPicks, QualityStocks, PoliticsAndMyPortfolio, AllPennyStocks, BullRally, CoolPennyStocks, FeedBlitz, Greenbackers, HotOTC, MadPennyStocks, OTC Markets Group, PennyInvest, Zacks, PennyStockVille, SmarTrend Newsletters, StockEgg, StockRich, StocksAlarm, Street Insider, Wall Street Mover and Penny Stock Rumble reported earlier on Blue Dolphin Energy Co. (BDCO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Blue Dolphin Energy Co. is primarily an independent refiner and marketer of petroleum products. The Company’s main asset is a 15,000 barrel per day (bpd) crude oil and condensate processing facility located in Nixon, Wilson County, Texas (Nixon Facility). In addition, as part of its refinery business segment, Blue Dolphin Energy also conducts petroleum storage and terminaling operations under third-party lease agreements at the Nixon Facility. The Company also owns and operates pipeline assets and has leasehold interests in oil and gas properties. OTCQX-listed and founded in 1986,, Blue Dolphin Energy is based in Houston, Texas.

Blue Dolphin Energy’s assets include Lazarus Energy, LLC (Refining Assets); and Blue Dolphin Pipe Line Company (Pipeline Assets). Its additional wholly-owned subsidiaries are Lazarus Refining & Marketing, LLC; Blue Dolphin Petroleum Company (Oil and Gas Leasehold Interests); Blue Dolphin Exploration Company (Exploration and Production); Blue Dolphin Services Co. (Administrative Services); and Petroport, Inc.

Blue Dolphin Pipe Line Company owns interests in and operates the Blue Dolphin Pipeline System (BDPS), which includes about 38 miles of pipeline from the Blue Dolphin Pipeline, onshore facilities and acreage in Freeport, Texas. Moreover, Blue Dolphin Pipe Line Company owns the Galveston Area Block 350 Pipeline and the Omega Pipeline.

The Nixon Crude Oil Processing Facility (Nixon Facility-56-acre) is near the border of Gonzales and Wilson Counties in Nixon, Texas, which lies in the heart of the Eagle Ford Shale and is within close proximity to some of the highest producing wells drilled in the Eagle Ford Shale so far. The Nixon Facility separates input crude oil and condensate into distillates (i.e. jet fuel) for sale into nearby markets, and also naphtha and atmospheric gas oil for sale to nearby refineries for further processing. Along with the processing capacity, the Nixon Facility has a storage capacity of 295,000 barrels.

Blue Dolphin Energy Co. (BDCO), closed Friday's trading session at $1.885, up 50.8%, on 287,861 volume with 535 trades. The average volume for the last 3 months is 287,861 and the stock's 52-week low/high is $0.2001/$1.98.

Reneo Pharmaceuticals (RPHM)

MarketBeat reported earlier on Reneo Pharmaceuticals (RPHM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Reneo Pharmaceuticals Inc. (NASDAQ: RPHM) is a clinical-stage pharmaceutical firm that is engaged in developing therapies for patients suffering from rare genetic mitochondrial illnesses.

The firm has its headquarters in San Diego, California and was incorporated in 2014, on September 22nd by Niall O’Donnell and Michael G. Grey. It operates as part of the scientific research and development services industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers across the globe, with a focus on those in the United Kingdom and the United States.

The company’s main priority is to develop therapies to improve the quality of life and daily function of patients with these rare illnesses. It develops therapies for mitochondrial illnesses that are often linked to the inability of the mitochondria in the body to produce ATP (adenosine triphosphate).

The enterprise’s product pipeline consists of a selective peroxisome proliferator-activated receptor delta agonist dubbed REN001, which is undergoing a phase1b trial evaluating its effectiveness in treating patients with glycogen storage disease type v and long-chain fatty acid oxidation disorders. This formulation is also undergoing phase 2b clinical trials testing its efficacy in treating individuals with primary mitochondrial myopathies.

The company recently announced its latest financial results, with its CEO noting that they remained focused on progressing its REN001 programs. The company has also made some changes to its leadership team, which will help support its planned growth in the short-term. This will in turn encourage more investments into the firm and help create shareholder value.

Reneo Pharmaceuticals (RPHM), closed Friday's trading session at $2.22, up 5.2133%, on 41,397 volume with 585 trades. The average volume for the last 3 months is 31,986 and the stock's 52-week low/high is $1.92/$12.78.

Scopus Biopharma (SCPS)

Schaeffer's, QualityStocks, MarketClub Analysis, MarketBeat and BUYINS.NET reported earlier on Scopus Biopharma (SCPS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Scopus Biopharma Inc. (NASDAQ: SCPS) is a clinical-stage biopharmaceutical firm that is engaged in the development of transformational therapeutics that target severe illnesses.

The firm has its headquarters in New York, the United States and was incorporated in 2017, on April 18th .Prior to its name change in December 2017, the firm was known as Project18 Inc. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm has three companies in its corporate family and serves consumers around the globe, with a focus on those in the United States.

The company is party to strategic partnerships with The Hebrew University of Jerusalem for its lead development program as well as other programs; the National Institutes of Health program; and the City of Hope.

The enterprise’s product pipeline comprises of immuno-oncology gene therapy programs for the treatment of a range of cancers. It develops a dual-action, orally available, hybrid small molecule that has been rationally designed and is an inverse agonist to the endocannabinoid system dubbed MRI-1867. This is also an inhibitor of inducible nitric oxide synthase. It also provides a CpG activator of transcription 3 inhibitors and signal transducer dubbed the Duet Platform.

The company recently added a new member to its board who has extensive experience in the biotechnology industry and will offer valuable insights to the company which may play a key role in the advancement of the company’s drug candidates as well as its growth and expansion.

Scopus Biopharma (SCPS), closed Friday's trading session at $0.3801, off by 2.4134%, on 15,620 volume with 96 trades. The average volume for the last 3 months is 15,620 and the stock's 52-week low/high is $0.3601/$7.68.

Talis Biomedical (TLIS)

MarketBeat reported earlier on Talis Biomedical (TLIS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Talis Biomedical Corp. (NASDAQ: TLIS) is a molecular diagnostic firm that is focused on the development of low cost, reliable, accurate and rapid molecular diagnostic tests for infectious illnesses at the point of care.

The firm has its headquarters in Menlo Park, California and was incorporated in 2013, on June 26th. It operates as part of the medical devices industry, under the healthcare sector. The firm has two companies in its corporate family and serves consumers in the United States.

The enterprise’s objective is to develop a diagnostic platform for infectious illnesses by combining real-time imaging, fluorescence and slip chips. It is involved in the development of a cloud-enabled molecular diagnostic platform dubbed the Talis One System. This system is comprised of single-use test cartridges, software and a compact instrument that has been designed to support a central cloud database and also offer central lab levels of accuracy. The system can be operated by an untrained user. It also develops assay kits for infections related to women’s health, respiratory infections and sexually transmitted infections. The enterprise also develops Influenza A and B tests to be included in its Coronavirus assay. This is in addition to developing a panel test for the detection of respiratory syncytial virus.

The company remains focused on scaling-up the manufacture of its coronavirus test systems, which will bring in additional revenues as well as delivering on its 2022 business objectives. This may positively influence investments into the company and help bolster its growth.

Talis Biomedical (TLIS), closed Friday's trading session at $1.03, up 0.980392%, on 166,137 volume with 854 trades. The average volume for the last 3 months is 137,442 and the stock's 52-week low/high is $0.901/$12.88.

Sangamo Therapeutics (SGMO)

MarketClub Analysis, The Street, Money Morning, MarketBeat, StocksEarning, Schaeffer's, SmarTrend Newsletters, StreetInsider, Top Pros' Top Picks, StockMarketWatch, Zacks, INO.com Market Report, BUYINS.NET, Kiplinger Today, TraderPower, Streetwise Reports, Marketbeat.com, The Street Report, QualityStocks, PennyOmega, Barchart, BestOtc, CRWEFinance, StockHotTips, CRWEWallStreet, Today's Financial News, DrStockPick, PennyToBuck, TheStockAdvisors, CRWEPicks, Greenbackers, Hit and Run Candle Sticks, Daily Wealth, TopStockAnalysts, Shah's Insights & Indictments, Wealth Insider Alert, StrategicTechInvestor, StreetAuthority Daily, Total Wealth, Wealthpire Inc., WealthMakers, CrashTrade, Trading Concepts, Trades Of The Day, Daily Trade Alert, TradersPro, SmallCapVoice, The Momentum Traders Network, Rick Saddler, Insider Wealth Alert, Investing Lab, Investors Alley, StockOodles, StockEgg, OilAndEnergyInvestor, Penny Invest and TopPennyStockMovers reported earlier on Sangamo Therapeutics (SGMO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sangamo Therapeutics Inc. (NASDAQ: SGMO) (LON: 0R1D) (FRA: GBY) (ETR: GBY) is a clinical-stage biotechnology firm that is engaged in the translation of science into genomic medicines which can transform the lives of patients by using platform technologies in genome regulation, genome editing, cell therapy and gene therapy.

The firm has its headquarters in Brisbane, California and was incorporated in 1995 by Edward O. Lanphier II. Prior to its name change in January 2017, the firm was known as Sangamo BioSciences Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers in the United States.

The company is party to strategic and collaborative partnerships with the California Institute for Regenerative Medicine, Hoffmann-La Roche Inc., F. Hoffmann-La Roche Ltd, Open Monoclonal Technology Inc., Genentech Inc., Sigma-Aldrich Corp, Dow AgroSciences LLC, Shire International GmbH, Novartis Institutes for BioMedical Research Inc., Sanofi S.A., Pfizer Inc., Kite Pharma Inc., and Biogen MA Inc.

The enterprise provides a technology platform dubbed zinc finger protein, which manufactures zinc finger nucleases that are used to modify DNA sequences by removing or adding certain genes. It also develops ST-502 to help treat synucleopathies like neuromuscular disease and Parkinson’s disease; ST-501 to treat tauopathies; a cell therapy to treat cancer dubbed KITE-037; and TX200, to help treat mismatched kidney transplant rejection.

The company, which is well positioned to advance its genomic medicines for patients in need of such, is focused on creating long term value for its shareholders, which will encourage more investments into the company and bolster its growth significantly.

Sangamo Therapeutics (SGMO), closed Friday's trading session at $3.72, up 1.3624%, on 1,607,074 volume with 10,980 trades. The average volume for the last 3 months is 1.607M and the stock's 52-week low/high is $3.375/$12.8297.

Theseus Pharmaceuticals (THRX)

The Street, Daily Markets, SmarTrend Newsletters, INO.com Market Report, SmallCap Network, PennyToBuck, BestOtc, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, PennyOmega, StockHotTips, StreetInsider, The Best Newsletters, Barchart, Greenbackers, FNNO Newsletters, FeedBlitz, Stockhouse, Stocks That Move, Stocks To Watch, StreetAuthority Daily and Investing Futures reported earlier on Theseus Pharmaceuticals (THRX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Theseus Pharmaceuticals Inc. (NASDAQ: THRX) is a biopharmaceutical firm that is focused on discovering, developing and commercializing targeted therapies to help treat cancer caused by treatment-resistant mutations.

The firm has its headquarters in Cambridge, Massachusetts and was incorporated in 2017, on December 29th by Victor M. Rivera, Wei Sheng Huang, Iain D. Dukes, David C. Dalgarno and William C. Shakespeare. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the globe.

The company is focused on its development programs which have been designed to address drug resistance mutations in various driver oncogenes, which are the mutated genes that facilitate the development of cancer. It remains committed to improving the lives of patients living with cancer by outsmarting cancer resistance. The company is developing next-generation TKIs (tyrosine kinase inhibitors) to address drug resistant mutations.

The enterprise’s pipeline is comprised of a 4th generation EGFR inhibitor that is active against an EGFR mutation known to cause resistance to osimertinib treatment in patients suffering from non-small cell lung cancer, known as C797S. It also develops a pan-KIT inhibitor dubbed THE-630, which is undergoing phase 1 clinical trials evaluating its effectiveness in treating gastrointestinal stromal tumors.

The firm is focused on advancing its pipeline of pan-variant targeted therapies and expanding its pipeline with another TKI program. This will make it better equipped to address the needs of patients with cancer, which will not only benefit the patients but also encourage more investments into the firm.

Theseus Pharmaceuticals (THRX), closed Friday's trading session at $6.01, up 1.5203%, on 166,284 volume with 2,522 trades. The average volume for the last 3 months is 166,168 and the stock's 52-week low/high is $5.705/$24.54.

Riot Blockchain Inc. (RIOT)

MarketClub Analysis, Schaeffer's, StocksEarning, InvestorPlace, StockMarketWatch, MarketBeat, TradersPro, Market Intelligence Center Alert, Zacks, The Street, Kiplinger Today, The Online Investor, TraderPower, Trades Of The Day, BUYINS.NET, Daily Trade Alert, Penny Stock 101, Market Intelligence Center, PennyStockLocks, QualityStocks, StockRockandRoll, StreetAuthority Daily, Trading Tips, Promotion Stock Secrets, Money Morning, StreetInsider, The Daily Market Alert, InvestorsUnderground, Investors Alley, TopPennyStockMovers and StockEarnings reported earlier on Riot Blockchain Inc. (RIOT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Riot Blockchain (NASDAQ: RIOT), an industry leader in Bitcoin mining and hosting, is reporting on its May 2022 productions and operations status. A highlight of the report includes the company’s production of 466 BTC, an estimated 104% increase over May 2021’s production of production of 228 BTC. In addition, the company reported that it held approximately 6,536 BTC, all produced by the Company’s self-mining operations, and sold 250 Bitcoin, generating net proceeds of approximately $7.5 million. Finally, the company reported a deployed fleet of some 43,458 miners, with a hash rate capacity of 4.6 exahash per second (“EH/s”). The company also noted that progress continued throughout the month at its 400 megawatt (“MW”) infrastructure expansion project located in Rockdale, Texas, with completion of the construction of the structure and exhaust louvres for Building D and installation of intake louvres for air cooling now beginning. Roofing and structure work on Building E is almost completed as well, along with the completion of installation of all medium voltage transformers. “During May, we continued to make progress on the ongoing expansion of our Whinstone Facility in Rockdale, Texas,” said Riot CEO Jason Les in the press release. “We’re proud to report that our first immersion building, Building F, is filled with approximately 23,000 S19 series miners. Approximately 7,000 of those miners are staged in the immersion-cooling tanks and are anticipated to be deployed pending installation of the final requisite components. Once these miners and other staged miners are fully deployed, our hash rate capacity is expected to increase to 5.4 EH/s. Additionally, we are initiating a project to refurbish our fleet of S17-Pro Antminers to improve their overall hash rate and efficiency. These enhancements are made possible by the improved operating environment facilitated by our immersion-cooling technology.”

To view the full press release, visit https://ibn.fm/DBn9E

About Riot Blockchain Inc.

Riot Blockchain’s vision is to be the world’s leading Bitcoin-driven infrastructure platform. Our mission is to positively impact the sectors, networks and communities that we touch.  We believe that the combination of an innovative spirit and strong community partnership allows the Company to achieve best-in-class execution and create successful outcomes. Riot is a Bitcoin mining and digital infrastructure company focused on a vertically integrated strategy. The Company has Bitcoin mining data center operations in central Texas, Bitcoin mining operations in central Texas and upstate New York, and electrical switchgear engineering and fabrication operations in Denver, Colorado. For more information about the company, visit www.RiotBlockchain.com.

Riot Blockchain Inc. (RIOT), closed Friday's trading session at $6.21, off by 9.607%, on 15,232,419 volume with 77,930 trades. The average volume for the last 3 months is 15.232M and the stock's 52-week low/high is $5.97/$46.28.

Elektros Inc. (ELEK)

We reported earlier on Elektros Inc. (ELEK), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Elektros (OTC: ELEK), an emerging leader in the electric vehicle industry, has announced that the company filed a patent pending last week with the United States Patent and Trademark Office for a revolutionary portable battery technology. According to the update, Elektros aims to perfect this technology over the next year to make it compatible with all Tesla models and other electric vehicles such as the Mercedes-Benz EQS. The portable battery contains an extension cord and allows consumers to plug in their electric vehicles at any time or place in case they do not have access to a traditional electric vehicle charger. Designed with the consumer in mind and depending on the type of electric vehicle, the portable charger may be stored neatly in the trunk, connecting with the vehicle's main battery and turning on with a simple switch on the dashboard when needed.

To view the full press release, visit https://ibn.fm/TwbaH

About Elektros Inc.

Elektros is an American electric transportation company that innovates mobility solutions for consumers and businesses. The automotive landscape faces existential disruption over the next decade to reach carbon neutrality. Elektros addresses this paradigm shift with mobility technologies that support sustainability for a transformative user experience. Elektros aims to present a compelling and completely new electric vehicle experience known as Elektros Sonic to consumers beginning as early as 2023. For more information about the company, visit www.ELEK.world.

Elektros Inc. (ELEK), closed Friday's trading session at $0.118565, up 7.7864%, on 2,422,212 volume with 390 trades. The average volume for the last 3 months is 2.422M and the stock's 52-week low/high is $0.0944/$8.50.

Freeport-McMoRan Inc. (FCX)

MarketClub Analysis, The Street, InvestorPlace, Schaeffer's, Kiplinger Today, SmarTrend Newsletters, StocksEarning, MarketBeat, Barchart, StreetAuthority Daily, StreetInsider, Trades Of The Day, TopStockAnalysts, Money Morning, Investopedia, Daily Trade Alert, Louis Navellier, VectorVest, Zacks, Marketbeat.com, Trading Markets, ProfitableTrading, The Growth Stock Wire, Daily Wealth, The Wealth Report, TheStockAdvisors, Top Pros' Top Picks, Wall Street Elite, All about trends, StreetAlerts, Leeb's Market Forecast, Streetwise Reports, TradingMarkets, The Online Investor, Market FN, INO.com Market Report, Dividend Opportunities, TheStockAdvisor, InvestmentHouse, StockTwits, Investor Guide, Investors Alley, Wealth Insider Alert, Investment House, Trading Concepts, Options Trader Elite, The Best Newsletters, Money and Markets, InvestorGuide, Market Intelligence Center Alert, Energy and Capital, Wyatt Investment Research, Bourbon and Bayonets, Darwin Investing Network, Investing Signal, AnotherWinningTrade, Buttonwood Research, Trade of the Week, Wealth Daily, The Motley Fool, MarketWatch, Investor Update, Profit Confidential, QualityStocks, Market Authority, Wall Street Daily, Street Insider, Trading Tips, TradingAuthority Daily, Stock Research Newsletter, Cabot Wealth, Wealthpire Inc., Super Stock Investor, InvestorsUnderground, AllPennyStocks, CNBC Breaking News, Daily Markets, FNNO Newsletters, Uncommon Wisdom, Normandy Investment Research and 24/7 Trader reported earlier on Freeport-McMoRan Inc. (FCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The Chinese government recently started loosening restrictions imposed when coronavirus infections were high. The relaxing of these restrictions, which had been choking the country’s economy, allowed industrial commodities to rise.

The virus is now considered to be under control in Beijing, with officials in Shanghai outlining their plan to revive the municipality after a two-month lockdown in the hopes that the virus will soon be under control in the region as well. The revival measures include making the purchase of cars cheaper, accelerating approvals for properties, and allowing the restart of manufacturing and all other metal-intensive areas, which were significantly impacted by the coronavirus pandemic.

Businesses in Shanghai have also been informed that they can resume their operations. However, most residents are yet to be told when they can leave their house compounds, with most of the public transport still being suspended. Additionally, private cars aren’t allowed to be on the road if they haven’t received prior approval.

The Purchasing Managers’ Index for the country is expected to remain in contraction while also recouping some of the losses it recorded in April following an improvement in output of steel and oil refining.

On a broader scale, the growth outlook of the Asian nation has reduced amid a coronavirus-zero policy, which may negatively affect it as the Chinese government increases stimulus to get its economy back on track.

Natixis senior economist Gary Ng stated that the most important thing to focus on was whether the country could keep on its reopening path, as investment and consumption wouldn’t rebound greatly if corporations and households continued to face the uncertainties that come with lockdowns. He added that in order to see a significant change in the zero-COVID policy in China, the world would need to wait until this year ended.

Capital Economics expects that among individual commodities, the demand for steel will likely remain low as policymakers continue discouraging housing speculation. The research firm predicts that by the year’s end, hot-rolled coil will have declined by 10% to reach 4,200 yuan ($629.48) per ton.

The demand prospects for copper also remain weak. However, the recorded extra spending on the power grid, which is the biggest consumer of the red metal, may improve its prospects and the earnings of mining companies such as Freeport-McMoRan Inc. (NYSE: FCX) over the medium to long term.

It is expected that the country will also take steps to clear high inventories of fuel that have accumulated during the long anti-coronavirus lockdowns. It may do so by issuing more export quotas, which will increase competition between refiners in the region.

Freeport-McMoRan Inc. (FCX), closed Friday's trading session at $41.33, off by 0.934803%, on 13,459,937 volume with 113,550 trades. The average volume for the last 3 months is 13.338M and the stock's 52-week low/high is $30.02/$51.99.

Canaan Inc. (CAN)

MarketClub Analysis, Schaeffer's, InvestorPlace, TradersPro, StreetInsider, Stockhouse, QualityStocks, AllPennyStocks, INO Market Report, BUYINS.NET, InvestorsUnderground, MarketBeat, Stock Fortune Teller, Trades Of The Day, StockMarketWatch, StocksEarning, The Online Investor, The Street, TopStockAnalysts and SmarTrend Newsletters reported earlier on Canaan Inc. (CAN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

While speaking on the sidelines of the World Economic Forum that ended recently in Davos, Switzerland, Ray Dalio, the billionaire founder and manager of the largest hedge fund across the globe said that blockchain is akind of digital gold.

Earlier in February, the Bridgewater Associates manager stated that he believed that cryptocurrencies are likely to be banned by different governments around the world. Despite this gloomy prediction, Dalio is such a firm believer in the future of cryptocurrencies that he has invested his personal money in Bitcoin, and his hedge fund has also invested considerable resources in digital assets.

While speaking in Davos, Dalio wasn’t too thrilled about the world economy. His speech showed that he had a gloomy picture of what is going on. He bases this outlook on the fact that today, the world is grappling with multiple threats, such as the ongoing COVID-19 pandemic, which isn’t showing any signs that it will end soon, especially in China. The other crises that he mentions are the fuel crisis and food shortages as well as the Russian invasion of Ukraine.

Dalio’s pessimistic tone was echoed by other dignitaries, such as the vice chancellor of Germany Robert Habeck, who said that the world is engulfed by four interlinked crises that cannot be resolved by focusing global attention on just one of those crises. The crises he singled out are the energy crisis, high inflation, food poverty and the global climate. Habeck says the only meaningful way is to tackle all these crises at the same time rather than trying to fix one at a time.

On what the U.S. Federal Reserve ought to do, Dalio says the Fed has no choice but to sell since everyone from private individuals, corporations and even the U.S. government was selling in order to finance deficits. Dalio went as far as to say that at the moment, cash was trash. This is because money is losing its purchasing power at a high rate because of rapidly rising inflation. His comment wasn’t only about the U.S. dollar but about all currencies around the world. He predicts that the value of cash is going to drop in relation to commodities and services.

It is in this regard that the billionaire looks at cryptocurrencies, such as Bitcoin, as a form of digital gold because investors can turn to it as a way of stabilizing their portfolios or hedging against losses due to instability in other asset classes such as stocks and bonds.

Such comments are likely to be welcomed by sector actors in the blockchain space, including Canaan Inc. (NASDAQ: CAN), because when a titan such as Ray Dalio speaks favorably about blockchain technology, the world listens.

Canaan Inc. (CAN), closed Friday's trading session at $3.67, off by 2.1333%, on 1,508,013 volume with 7,496 trades. The average volume for the last 3 months is 1.508M and the stock's 52-week low/high is $2.56/$11.50.

The QualityStocks Company Corner

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, today announced details for the 2022 LD Micro Invitational. SRAX will host the prominent investor conference on June 7-9 at the Four Seasons Hotel Westlake Village, as well as via its Sequire Virtual Events platform. LD Micro is the host of the most influential conferences in the small-cap world. Following last October’s success of the LD Micro Main Event, SRAX is providing a virtual option for those unable to attend the physical conference. The event, which expects to feature over 200 companies and several influential keynotes, will focus on newcomers and, in the words of LD Micro Founder Chris Lahiji, will introduce companies on the “cusp” of doing big things. Interested parties should visit https://www.meetmax.com/sched/event_82067/conference_home.html to apply for the invitation-only, in-person event and https://ldinv12.mysequire.com/ to register to attend the virtual conference. For more information, view the full press release

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Friday's trading session at $3.83, up 3.5135%, on 124,271 volume with 627 trades. The average volume for the last 3 months is 124,271 and the stock's 52-week low/high is $3.00/$7.29.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, and its CEO and chair David Michery are spotlighted during an interview on Benzinga’s All Access Series. The interview is slated for today, June 3, 2022, at 11 a.m. ET. Michery and All Access host Spencer Israel will discuss the company, including its upcoming “Strikingly Different” U.S. test drive tour, which will include stops at 19 cities across the country. Benzinga’s All Access show is a valuable source for those who want to learn more about the latest-trending stocks and investment opportunities. The show features live CEO interviews, due diligence presentations and Q&As with company leaders. “I invite everyone to join us tomorrow on the interview with Benzinga,” said Mullen CEO and chair David Michery in the press release. “The Benzinga All Access Series is a great opportunity for everyone to listen in and hear the latest from me on Mullen’s EV efforts.” To view the full interview, visit https://ibn.fm/o5DVz. To view the full press release, visit https://ibn.fm/6Ghng. Researchers from Rice University in Houston, Texas, have come up with a novel process that has the potential to revolutionize recycling and sustainability in the nascent EV sector. At least 27 million vehicles are shredded across the world each year, with the United States accounting for 15 million of them. Most of these shredded vehicles are incinerated. In Europe, old vehicles are sent back to their manufacturers, which are required to recycle 95% of a vehicle and landfill just 5%. This is often too much for most manufacturers to handle, and they resort to scrapping the old cars. Now Rice University researchers have developed a method to convert material from old internal combustion engine vehicles to graphene, one of the strongest, most durable, and lightweight materials on the planet. This material would make electric vehicles much more durable while keeping their weight down, increasing battery life and fuel efficiency. The material had been so expensive, generally costing $200,000 per ton, that it was referred to as black gold. Thanks to flash Joule heating, scientists will now be able to make it from plastic garbage, and manufacturers of EVs, such as Mullen Automotive Inc. (NASDAQ: MULN), could use this material.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Friday's trading session at $1.27, up 3.252%, on 95,589,622 volume with 92,410 trades. The average volume for the last 3 months is 93.353M and the stock's 52-week low/high is $0.52/$15.90.

Recent News

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

  • Correlate Infrastructure Partners Inc. (CIPI) is a developer of green energy solutions for commercial clients, playing a role in global efforts to reduce carbon emissions by improving the climate impact of buildings and other business facilities
  • CIPI’s two subsidiaries — Correlate, Inc. and Loyal Enterprises LLC (dba Solar Site Design) — provide complementary approaches to advising commercial clients on green energy solutions, developing those solutions and financing them
  • Correlate uses modern tools for data analysis that provides clients with ESG-friendly reporting capabilities that are increasingly in demand from investors and regulators
  • A recent report by the SustainAbility Institute by ERM found corporate issuers on average are spending $677,000 per year on climate-related disclosure activities and investors are spending $1.372 million on average to obtain company climate data

Innovative business world-leading magnate Elon Musk’s praise of China’s global dominance in the renewable energy and electric vehicle markets thanks to the country’s savvy acquisition of mineral resources and aggressive production quotas is providing Western nations new impetus for finding common ground with the megalithic Asian society on climate change. A report on Musk’s recent comments notes that China is the world’s largest emitter of carbon dioxide, known to be the biggest contributor to global warming, thanks to the nation’s world-leading consumption of coal, but that the country is also  the world’s leading producer of hydro, wind and solar power and that is the world’s largest seller of automobiles running on electric batteries and hydrogen fuel cells (https://ibn.fm/L4QTt). Since 2014, the relationship between China and the United States in working to reduce carbon emissions has been a centerpiece of global agreements on fighting climate devastations. While the White House distanced itself from China and climate change efforts between 2016 and 2020, the current U.S. administration has reprioritized renewable solutions (https://ibn.fm/bl2Jk). In the United States, Louisiana-based Correlate Infrastructure Partners (OTCQB: CIPI) is playing a smaller but nonetheless vital role in helping to move consumers toward green energy use with the hope of preventing catastrophic climate change.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.

Subsidiaries

Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Friday's trading session at $1.19, up 13.3333%, on 3,300 volume with 1 trade. The average volume for the last 3 months is 3,300 and the stock's 52-week low/high is $0.30/$3.25.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Advanced Container Technologies (OTC: ACTX), the exclusive U.S. distributor of GrowPods, is seeing interest in the environmentally controlled micro-farms that allow cultivation of ultraclean crops year-round. According to a recent article that contains excerpts from a GreenBiz piece titled, “How Vertical and Indoor Farming Can Supplement the Food Supply Chain,” innovators have developed new technologies such as indoor and vertical farms designed to supplement outdoor farming and solve the issue of limited cultivation land. The piece notes that “the systems often recirculate water, which can be more efficient than how water is used for other types of crops. Light and temperature can also be controlled, and since there is no exposure to pests, no chemistry is needed…. [The farms] can be built anywhere. That means food such as leafy greens can be grown closer to population centers.” Experts also believe that while indoor and vertical farming will not feed the world, it can supplement the supply chain. “These are only a few of the advantages that GrowPods, which are self-contained, automated, indoor micro-farms, offer users. These innovative containerized growing systems are designed with functionality and ease of use in mind. The pods are configured to optimize plant growth while minimizing labor; setup is quick and simple, no pesticides are needed, and the containers produce harvests all year long.” To view the full article, visit https://cnw.fm/vrVue

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.

Products

Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.

Containers

ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.998, up 33.0667%, on 1,405 volume with 5 trades. The average volume for the last 3 months is 1,405 and the stock's 52-week low/high is $0.66/$3.575.

Recent News

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its proprietary EMBARK program is the focus of a recent article in the “Frontiers in Psychology” journal. The peer-reviewed article discusses the company’s model of psychedelic-assisted psychotherapy that integrates leading clinical approaches to promote effective facilitation and supportive healing with psychedelic medicines. Titled “Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model,” the article appears in the June 2, 2022, issue of the publication, which is the largest journal in the field of psychology. The article discusses EMBARK’s six clinical domains (existential-spiritual, mindfulness, body aware, affective-cognitive, relational and keeping momentum) and reviews the strengths and limitations of existing psychedelic-assisted psychotherapy approaches and evidence-based therapies. In addition, the company also announced it has created a 28-member team of faculty and advisors who will lead the company’s EMBARK Psychedelic Facilitator Training Program. Recognized leaders in their field, the team members will oversee Cybin’s innovative new program. “It’s a pleasure to see our work published in this respected journal,” said Cybin chief clinical officer and EMBARK cocreator Alex Belser in the press release. “In developing EMBARK, we looked at 17 models of psychedelic-assisted psychotherapy, and we noticed that many are missing critical elements: a focus on ethics, on human relationships, on the body as a site of somatic healing, and on evidence-based practices. We designed EMBARK to overcome some of these limitations as an integrative model of psychedelic therapy. We’d like to honor the contributions of many teachers and leaders in the field who have helped chart this course.” To view the full article, visit https://ibn.fm/2mwT8. To view the full press releases, visit https://ibn.fm/RfdAH and https://ibn.fm/jMUjh

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Friday's trading session at $0.785, up 4.9185%, on 813,854 volume with 2,085 trades. The average volume for the last 3 months is 810,594 and the stock's 52-week low/high is $0.3903/$3.38.

Recent News

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) today announced that it has filed a U.S. non-provisional patent application for the company’s “Modular Transportable Clean Hydrogen-Ammonia Maker” with the United States Patent and Trademark Office. This claims priority out of FuelPositive’s U.S. provisional patent application filed on June 7, 2021, and elaborates upon FuelPositive’s inventive concepts. “We continue to refine our proprietary systems and apparatus in the process of constructing our demonstration systems,” said Ian Clifford, CEO and board chair of FuelPositive. “There is a worldwide shortage of ammonia and fertilizer and seriously compromised supply chains, making our decentralized and containerized on-site green ammonia production systems acutely needed. We are being approached daily by people and companies from all over the world who want our systems so they can control their supply, timing and pricing, while dramatically reducing carbon emissions. By filing these patent applications, we are setting ourselves up to be able to deliver green anhydrous ammonia and its derivatives wherever the technology is needed in the coming years.” For more information, view the full press release

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

  • Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
  • Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
  • End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Friday's trading session at $0.1275, up 2%, on 172,142 volume with 29 trades. The average volume for the last 3 months is 172,142 and the stock's 52-week low/high is $0.09/$0.31.

Recent News

AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF)

The QualityStocks Daily Newsletter would like to spotlight AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF).

A new study has found that women who experience complications associated with the development of hypertension during pregnancy have a heightened risk of developing cardiovascular disease as they get older. This study is a comprehensive review assessing links between future cardiovascular events in women who have had gestational hypertension or preeclampsia. Preeclampsia is a serious complication characterized by a sudden increase in blood pressure, which is dangerous for both the baby and the mother and affects the body’s organs. On the other hand, gestational hypertension is marked by a rise in blood pressure while a woman is pregnant. Both conditions are usually diagnosed after five months of pregnancy. Several companies, including AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF), have formulations that can help in the management of hypertension so that it doesn’t worsen to a level that triggers other health complications.

AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) is a fully integrated, publicly traded, early-stage life science enterprise dedicated to delivering therapeutic interventions to public health through discovery, innovation and successful collaborations in the life science industry. The company’s leadership drives discovery programs for clinical complexities presented by malnutrition, viral infectious diseases and the inflammatory response system.

AREV’s business model leverages the core competency of producing proprietary compounds through its innovative extraction methodologies, scientific advisory board (SAB), experienced staff, and executive leadership to drive its product pipeline. AREV’s strategy is to generate revenue from selling its branded products via its online technology platform, Medicine Merchant™, an enterprise marketing platform built to enable consumers to have access to novel therapeutic approaches to human nutrition, endemic diseases, and neglected chronic related co-morbidities. The company also expects to generate revenue from toll processing and government procurement of its products that address malnutrition and related health issues.

AREV is focused on innovations in biomedicine and maintains a significant footprint in clinical human nutrition utilizing proprietary protein blends and terpenes, complimented with vitamins and minerals. The company has utilized its expertise to design and deliver innovation in therapeutic interventions using its exclusive botanical, fungi and marine compounds to address medical conditions driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV uses its proprietary extractions allowing characterizations from botanical and marine sources in therapeutic foods and medicines that comprise its development pipeline.

Development of AREV’s pipeline is fostered by collaborations with academic centers, clinical research organizations and government institutions committed to facilitating discovery of promising new clinical approaches presented in peer reviewed journals. AREV operates under the guidance of its SAB and a growing number of strategic collaborations with CROs and academic research centers, including the Linus Pauling Institute at Oregon State University.

AREV is a member of both BIOTECanada and The Biotechnology Industry Organization (BIO):

  • BIOTECanada is the national industry association with over 200 members located nationwide, reflecting the diverse nature of Canada’s health, industrial and agricultural biotechnology sectors.
  • BIO is the world’s largest advocacy association representing member companies, state biotechnology groups, academic and research institutions, and related organizations across the United States and 30+ countries.

Products

AREV’s end-product and target categories include therapeutic interventions, botanical drugs, ready-to-use therapeutic food (RUTF), enteral nutrition formulas and early-stage small molecule antiviral therapeutics demonstrating novel mechanisms of action.

Wright and Well Branded Line

Wright and Well Branded Line is the company’s branded line of therapeutic cannabinoid and terpene-based formulations. The topical line includes solutions for burns, wounds, skin disorders and muscle relief, as well as a lubricant for intimacy. The oral line addresses inflammation, heart health, high blood pressure and viral infections. These products are currently produced at CBD99, a licensed processor in Sandy, Oregon. The company also has a strategic relationship with a Canadian licensed hemp and cannabis processor in Vancouver, British Columbia.

SUS-TAINN™

The company’s products in the RUTF category are branded under SUS-TAINN™ (Superior Utility Supplementation Therapeutic Agent for Indicated Nutritional Needs). SUS-TAINN™ is the flagship line of products stemming from AREV’s collaboration with Voynich Biosciences.

RUTFs like SUS-TAINN™ are the cornerstone to international famine response and currently represent more than 20 percent of public health commodity procurement spending. SUS-TAINN™ is purchased by agencies ranging from the U.S. Department of State AID for International Development to the World Food Program and is distributed by an increasingly substantial number of non-governmental organizations.

RESTORE™

The company’s enteral nutrition product is branded as RESTORE™. For patients experiencing caloric compromise, enteral nutrition, a liquid form of nourishment, is often required. RESTORE™, the initial enteral formulation from AREV, is based on organic plant nutrition for patient populations who have demonstrated overt clinical need for rational enhanced caloric intake and micronutrient supplementation.

RESTORE™ provides a proprietary blend of high-quality proteins, antioxidants, minerals and proven anabolic agents, combined with pre- and probiotics. The company plans to submit for Medicaid formulary inclusion and reimbursement designations in various jurisdictions characterized by the Ryan White CARE Act during the second half of 2022.

REV-I1™

REV-I1™ is the company’s small molecule drug discovery model for phytomedicinalization, based on advanced computational characterization and next generation affinity selection that affords new opportunities in HIV antiretroviral research. REV inhibition offers a critical approach to inhibiting HIV replication and addressing viremia in highly conserved sanctuary regions.

Phytomedicinal therapeutic discovery and development offer clinically viable approaches to a wide range of scientific challenges that currently elude successful contemporary interventions. A cornucopia of diverse validated compounds allows AREV to explore a distinguished range of promising approaches that are in stages of pre-clinical validation. Combining AREV’s versatile extraction capability with highly sensitive analytical techniques (LC-MS, MS-MS) is expected to allow new medicinal chemistry to be identified and characterized, leading to therapeutic candidates in the company’s commercial drug discovery platform.

Market Overview

A report from Verified Market Research valued the global plant protein market at $29.4 billion in 2020 and forecast that it could surpass $162 billion by 2030, which would make up 7.7% of the global protein market, according to a report released in August by Bloomberg Intelligence.

The RUTF market was valued at $363.72 million in 2019 and is projected to reach $807.89 million by 2027, growing at a CAGR of 10.5% for the forecast period. The market is primarily driven by the efforts of governments and non-governmental organizations to reduce the rate of severe acute malnutrition. Moreover, changing trends and growing developments related to diet-related deficiencies, as well as increasing incidences of famine and disasters, are likely to fuel the growth of the RUTF market in the near future, according to the report.

Management Team

Michael Withrow is the founder, chairman and CEO of AREV. He is a successful natural products and technology entrepreneur with more than 25 years of experience. He has started and sold companies and has worked with companies such as CAVA Health Care (formerly Alternative Extracts Inc.), North American BioExtracts Inc., and Canadian Pacific Phytoplankton Ltd. He has also served as president and CEO of a specialty cannabis technology company.

Kevin Phelps, CPA, is a director at AREV. He is CEO and president of Immune Therapeutics Inc., a bio-pharmaceutical company. He began his career with Price Waterhouse before joining Eastman Kodak Company as part of an executive team that successfully spun out the Bio Products Division into Genencor International Inc., an international industrial bio-chemicals company. He later joined Trillium Group, a regional private equity firm, as a partner, where he served on behalf of the firm as CFO of Vaccinex Inc., a vaccine development company, and chairman of AccuMed Inc., a medical device company. He has served as Chairman of Oyagen, a biotech that over the past decade has developed drug discovery methods that have enabled it to explore vulnerabilities in HIV, Ebola and coronaviruses.

Denby Greenslade is corporate secretary and interim CFO at AREV. She has served as corporate secretary and director for several companies in the mining, biotech and IT industries and has more than 15 years of corporate secretarial, corporate governance, and securities regulation experience. She graduated from Simon Fraser University with a Bachelor of Arts in Communication.

Allan Echino is a director at AREV. He was a founder and director of Corlac Resources, an oil producer, and Calroc Industries, an oil service company based in Alberta. Mr. Echino arranged funding for a licensed producer in the cannabis sector and quickly learned the business and health benefits of cannabis and mushrooms.

Mel Maxwell is a director at AREV. During his 40-plus year career, he has founded six companies. His degrees in business and computer science initially took his career toward IT ventures that entailed software development, IT consulting, e-commerce solutions, real estate development, pathogen remediation solutions and wholesale vehicle aggregation. He finds continued enjoyment in consulting with other businesses and entrepreneurs.

Scientific Advisory Board

Roscoe M. Moore, Jr., DVM, MPH, PhD, a former United States Assistant Surgeon General, provides strategic planning for AREV’s nutritional and drug discovery platforms as chairman of the company’s scientific advisory board. Dr. Moore is a member of the board of advisers of the Institute of Human Virology (IHV) and the board of directors of the Global Virus Network associated with IHV, University of Maryland Medical Center. IHV is the first research institute in the U.S. to link basic science, population studies, and clinical trials in an effort to develop new vaccines and treatments; its 80 faculty members contribute to research on pandemic pathogens, ranging from COVID-19 to HIV.

Dr. Moore served with the United States Department of Health and Human Services (HHS) and was responsible, for the last 12 years of his career, for global development support within the Office of the Secretary, HHS, with primary emphasis on implementing innovations in essential health care commodity procurement programs for resource-challenged countries. Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service, entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Rear Admiral. Dr. Moore worked at the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming senior epidemiologist within the National Institute for Occupational Safety and Health of the U.S. Centers for Disease Control and Prevention (CDC), where he also served as an epidemic intelligence service officer.

Robert Melamede, PhD, received his doctorate in molecular genetics and biochemistry from the University of the City of New York Graduate Center, focusing on base excision repair of free radical damages in DNA. For decades, he led laboratory efforts in a world-class, federally funded lab, where he discovered endonuclease VIII. Dr. Melamede did a sabbatical at the Scripps Institute and subsequently established an in vitro monoclonal antibody facility at the University of Vermont, developing antibodies to free radical damages in DNA and to DNA repair enzymes. Working with a collaborator, Dr. Melamede worked on metabolism and cancer cells as a professor and chair of the biology department at the University of Colorado at Colorado Springs. He co-founded Cannabis Science Inc., a public company, retiring as the company’s chief executive in 2014. Dr. Melamede continues his innovative research in the private sector.

Harold Smith, PhD, is the founder, CEO, and president of Oyagen Inc., a biotechnology company developing therapeutics for various disease states, including HIV and cancer. Dr. Smith is also a tenured professor of biochemistry and biophysics at the University of Rochester, School of Dentistry and Medicine, with additional appointments as a professor in genetics and pathology and as a member of the Center for RNA Biology.

Richard Van Breemen, PhD, is a Professor of Medicinal Chemistry in the Department of Pharmaceutical Sciences of the College of Pharmacy at Oregon State University. His research interests include cancer prevention by dietary antioxidants and prostate cancer prevention by the carotenoid lycopene, mass spectrometry-based pharmacological screening of natural products and combinatorial libraries for drug discovery, and high throughput screening to assess drug metabolism, toxicity and bioavailability. Dr. Van Breemen made The Analytical Scientist’s Power List in 2020 and 2021. His work in biomedical mass spectrometry earned him an initial spot, and he clocked in the Top 100 analytical scientists from around the world on the Power List in 2021.

Dr. Blake Hawley is the founder & CEO of Motega Health Inc. Dr. Hawley has worked in animal health, pharma and food across 23 countries and four continents. He holds an MBA from KU and his doctorate in veterinary medicine and zoology degrees from NC State. He serves on multiple non-profit advisory boards, including the KU MBA Advisory Board. Dr. Hawley is a 2017 graduate of Pipeline Entrepreneurs and a graduate of the Village Capital Agricultural 2016 Entrepreneur Cohort.

Dr. Hawley previously served as the General Manager of Australasia; Regional General Manager of Russia and Central Eastern Europe (consisting of 22 countries); and Managing Director of the United Kingdom and Ireland for Hill’s Pet Nutrition, a division of Colgate-Palmolive. His experience includes 10 years of profit and loss responsibilities in these territories, with consistent double-digit annual revenue growth in each of the 10 years. He oversaw products competing in the arthritis, dermatology, obesity, gastrointestinal, urinary, and cancer markets, among others. Dr. Hawley also has background in e-commerce, data analytics, and social media and most recently served as Worldwide Director of Global Digital for Hill’s Pet Nutrition.

Uma Dhanabalan, MD, MPH, FAAFP, MRO, CMS, advises AREV on product development and formulation. She is the founder and CEO of Global Health & Hygiene Solutions LLC, whose mission is to promote wellness and prevent illness locally and globally and runs an independent practice at Uplifting Health & Wellness in Cambridge, Massachusetts. Dr. Dhanabalan, a fellow of the American Academy of Family Physicians, graduated from UMDNJ, Newark, New Jersey, with her medical degree and trained in family medicine at MUSC in Charleston, South Carolina; she earned her master’s degree in public health from Harvard’s School of Public Health in Boston, Massachusetts, and continued her training at Harvard in occupational and environmental medicine.

Special IP Advisor

Douglas Sorroco practices in all areas of intellectual property law including patent, trademark, copyright, technology, and e-commerce and assists clients with intellectual property matters requiring litigation, licensing, technology counselling and complex transactions.

Mr. Sorroco is ranked in Band 1 (the top band) for intellectual property law by the highly regarded Chambers USA: America’s Leading Lawyers for Business 2021, and he was selected for inclusion in The Best Lawyers in America® 2022 for Litigation – Intellectual Property, Litigation – Patent, Patent Law and Technology Law. In 2021, Best Lawyers named him the Oklahoma Lawyer of the Year for Technology Law. In 2021, Managing Intellectual Property continued to rank Doug as an IP Star. Mr. Sorroco was selected for inclusion in Oklahoma Super Lawyers 2021 and was also selected by attorney peers for inclusion in Oklahoma Super Lawyers – Rising Stars Edition (2010).

AREV Life Sciences Global Corp. (OTC: AREVF), closed Friday's trading session at $0.1206, even for the day. The average volume for the last 3 months is 2,500 and the stock's 52-week low/high is $0.0655/$0.32616.

Recent News

Nowigence Inc.

The QualityStocks Daily Newsletter would like to spotlight Nowigence Inc.

  • Vision, integrity and critical thinking are key skills for an effective executive team
  • The Nowigence executive team has garnered an estimated 80 years of experience in leading companies around the world
  • Company looking to capitalize on $20-billion-plus market opportunity with Pluaris, its cloud-based knowledge management tool

A recent Indeed article noting the top skills of an effective executive leadership team listed vision, integrity and critical thinking as among the most important (https://ibn.fm/FDaW6) — all three of which are deeply evident in the top executives at Nowigence. Nowigence is an innovative software-as-a-service (“SaaS”) company focused on developing and bringing to market Pluaris(TM), a comprehensive, ready-to-use artificial intelligence (“AI”) platform.

Nowigence Inc. is a fast-growing SaaS (Software-as-a-Service) company that develops and sells a ready-to-use artificial intelligence (AI) platform called Pluaris™ that automates reading and analysis of textual data. Individuals, teams, and enterprises can now quickly distill knowledge buried in narrative-intensive documents instantaneously from various data sources, both public and private.

Pluaris is created for those who want to read more in less time. It is a Personal Knowledge Management (PKM) tool that generates an annotated data feed based on your topics of interest and automatically creates a permanent personal knowledge base from your feed and private uploads. It has human-like capabilities for comprehending textual data. It summarizes, provides precise answers to questions asked, analyzes different data perspectives, discovers new connections, creates organized nested notes, and allows teams to work collaboratively by sharing in real-time from anywhere in the world to draw informed conclusions.

By integrating state-of-the-art data processing techniques in an intuitive interface at an affordable subscription price, Nowigence puts the power of data science in the hands of consumers. It helps individuals, teams, and organizations to quickly build expertise on one or multiple topics by generating a trove of critical information.

Nowigence targets two user types that rely heavily on fast and accurate research as primary adopters of the Pluaris platform. The first is knowledge workers of all kinds – anyone whose job is to “think for a living” like marketing professionals, researchers, legal professionals, academics, journalists, editors, scientists, and other professionals. The second are individual users who are life-long learners, hobbyists, and enthusiasts of all stripes.

Rather than spending time reading information to gain knowledge from one source at a time, users of Pluaris can gain knowledge from hundreds or thousands of sources in seconds. Keyword-based search-and-retrieval applications don’t open documents, nor read their content, nor extract key points, conduct cause and effect analysis or answer questions specifically. Pluaris includes all those features and goes one step further, with its semantic capabilities to empower users with interpretations of retrieved information. Nowigence estimates this feature alone can save typical researchers between one and three hours per workday. The platform also reduces “noise” by extracting only important and relevant information on every topic being monitored or researched. This helps cut down on information overload, a major source of workplace stress.

Pluaris Builds Intelligence

The Problem

In the modern world, virtually everyone needs to consume a tremendous amount of text-based information, in both our personal and professional lives, but doing so is exceptionally challenging because of:

  • Information Overload: For virtually any significant topic of interest, the amount of textual information available and continually generated is vastly more than can be consumed by an individual.
  • Pervasive Distractions: Thanks to modern technology, we are constantly bombarded with new inputs (e-mails, instant messages, social media, and more) reducing our attention span, leading all too often to TL;DR (Too Long, Didn’t Read).
  • Highly Imperfect Human Recall: The information that we do find time to read is easily forgotten. Even if we retain some of the key insights, the details are almost certainly lost.

Even when working in teams, we often end up researching the same content as our colleagues, and too much of the information acquired by one individual is lost in translation with the communication process to others.

Pluaris

Nowigence has worked with stalwarts and pioneers in the fields of Machine Learning (ML) and Natural Language Processing (NLP) from its early days. The company was keen to solve the big problem of the information age – too much data exists and cannot be processed manually.

Pluaris is designed to be used by regular people from day one with no need for extensive training. The platform is used across different functions and sectors, adapting to clients’ ever-changing needs. Its state-of-the-art no code editing gives organizations the flexibility to improve and tailor their results without hiring data scientists, and real time information retrieval ensures the client never misses any piece of intelligence.

Pluaris adapts to the unique needs by which individuals absorb knowledge. It doesn’t impose structured or rigid methodology. Real time operation means that Pluaris will deliver outputs instantaneously with a click.

A Nowigence team of experts spent three years training Pluaris to understand the context of every sentence it reads. If Pluaris does make an error in contextual interpretation, the user can correct it, which will instantly give the correction precedence over the ML’s algorithmic outputs. This takes away the biggest criticism against AI/ML platforms, that annotating (labeling) data and developing training datasets to build models takes too much time and effort from internal teams.

Use Cases

I need to stay on top of the latest news for my industry. Pluaris automatically retrieves and analyzes news on your topics of interest every day, so you can quickly scroll through an annotated news feed on your phone, tablet or laptop, while finishing your morning coffee.

Example: A Pluaris enterprise customer was interested in tracking news and events in the telecom industry. Nowigence was able to quickly create and then fine-tune a list of topics to monitor. In less than a week, they had an annotated news feed covering the telecom industry available to their team.

I have to come up to speed on a new topic as quickly as possible. Upload a few related websites and documents to Pluaris and within minutes you are exploring this new area of interest, scanning the summaries, gaining new insights about this topic, and finding new keywords to broaden your search and deepen your understanding.

Example: A customer who was already using Pluaris for business intelligence decided to use his account to make improvements in his health after he received a report from his doctor of a high fasting blood sugar level.

  • He uploaded a few research reports to Pluaris, read through the summaries, and explored the annotated labels. Based on that analysis, he set up Pluaris to monitor topics such as “lowering fasting blood sugar” and “low glycemic food.”
  • From those results, he built an action list of daily habits for diet and fitness and, within a couple months, brought his fasting blood sugar level back down.

I want to be able to access the information I’ve read in the past and synthesize it with my current understanding. As you continue to add more and more information to the system over time, Pluaris never forgets. You are building a knowledge base of the information that is most relevant to you.

Example: A Pluaris user at one of the world’s largest aluminum mining companies was tasked with preparing talking points for her manager for an upcoming investor meeting. Over time using Pluaris, she had built a database of documents, including transcripts, notes, Q&A sessions, speeches, annual reports, and internal documents, some of which were from previous investor meetings. She was able to quickly explore that database through the Pluaris Dashboard and using various filters. She then pulled this information together in a Pluaris Notebook and shared that note directly with her boss.

Market Outlook

Pluaris users include:

  • Knowledge WorkersGartner estimates there are more than 1 billion worldwide as of December 2019.
  • Students in Higher Education: ICEF estimates there are 250 million worldwide as of 2020. This is Nowigence’s initial target group from a market penetration perspective.
  • Personal/Home Use: Statista estimates there are 4.7 billion active internet users worldwide as of January 2021.

Nowigence offers tiered pricing, starting at $10/month/user for individuals, while team and enterprise users, who have access to more features to facilitate collaboration and integrations to other enterprise tools, start at $45/month/user.

As a result, the Total Available Market (TAM) is more than a billion users and over $1 trillion. The Market Opportunity (the Serviceable Obtainable Market or SOM) for Nowigence is $11 billion in the combined PKM and Cognitive Computing space defined by Pluaris.

This market is growing rapidly too. The Cognitive Computing market alone was valued at $8.87 billion in 2018 and is projected to reach a value of $87.39 billion by 2026, growing at a CAGR of 31.6% from 2019 to 2026, according to Allied Market Research.

Nowigence offers differentiated value compared to other Personal Knowledge Management (PKM) tools, which have reached as many as 250 million users (Evernote) and have shown rapid adoption (Roam Research reached 60,000 users and $1 million ARR within 6 weeks of launching paid plans). Unlike Pluaris, these tools do not automatically monitor public or private sources to add to your knowledge base, nor do they provide summaries or extract intelligence. Pluaris differs from search engines as well, in that search engines do not access or store personal knowledge, and they also do not summarize or extract intelligence.

Management Team

Anoop Bhatia is the founder and CEO of Nowigence Inc., where he has worked full-time since 2015. Previously, he worked as a global operation strategic transformation leader for Momentive Performance Material (formerly GE Silicones). He has worked for over two decades in various General Electric companies across different countries, including the U.S., India, The Netherlands and Germany. He played a key role in establishing GE Silicones as the first-ever wholly owned foreign subsidiary established in India in 1996. He received his Bachelor of Engineering in Chemical Engineering from BITS in India and did his post-graduate studies in management from Heriot-Watt at Edinburgh in Scotland.

Gordon Haupt is the Chief Technology Officer at Nowigence. He has more than 20 years of experience building and leading diverse engineering and operations teams, and a strong technical background in machine learning, signal processing, and statistical data analysis, including applications in speech and text, biotechnology, and computer vision. He is a named inventor on 15 issued patents and is experienced in all phases of engineering development and operations. He holds a B.S. degree in Engineering Mechanics from the University of Wisconsin and M.S. and Ph.D. degrees from Stanford University in Aeronautics and Astronautics.

David Evans is the company’s acting CFO & General Counsel. As an attorney and licensed CPA in the state of New York, he has extensive experience in multistate and international tax policies and guidelines, federal taxation laws, mergers and acquisitions, including valuation of closely held businesses. He is a contributing author to the New York State Tax Service, a six-volume publication of NYS tax laws and regulations. His prior experience includes being a Managing Director for UHY Advisors LLC, a board member and chairperson of the Tax Division Executive Committee of New York State Society of Certified Public Accountants and a past president of the Estate Planning Council of Eastern New York. He holds degrees from Hofstra University and State University of New York at Buffalo.


Recent News

chart

Golden Matrix Group Inc. (NASDAQ: GMGI)

The QualityStocks Daily Newsletter would like to spotlight Golden Matrix Group Inc. (NASDAQ: GMGI).

Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, today announced financial results for its second fiscal quarter ended April 30, 2022. Among the highlights, the company reported Q2 revenues of $8,482,743, a 221% increase as compared to the same quarter last year. The company also noted 15 consecutive quarters of profitability. “We are pleased with the financial results of our second quarter as a company with both B2B and B2C verticals,” said Golden Matrix CEO Brian Goodman. “During the quarter we implemented upgraded technology and stronger accounting controls to improve cash flow and profitability at RKings. With the Tournament Platform’s added features and functionality, we expect steady increases in both the monthly number of skill tournaments and participants; and, because this robust platform gives RKings’ tournament players immediate access to a growing number of exciting prize competitions, we expect this third quarter and future quarters to generate increasing revenues and profits.” For more information, view the full press release

Golden Matrix Group Inc. (NASDAQ: GMGI), based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds turnkey online casino solutions for gaming operators as well as configurable and scalable white-label gaming platforms for international customers, located primarily in the Asia-Pacific region. GMGI’s gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications.

GMGI’s sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with U.S. law.

Golden Matrix, through a subsidiary, also runs a pay-to-enter prize competition in the United Kingdom and Ireland.

The company’s shares began trading on the Nasdaq under the symbol ‘GMGI’ on March 17, 2022. Golden Matrix shares were previously traded on the OTCQX Best Market.

For the quarter ended January 31, 2022, the company reported revenue of $8.88 million, an increase of 355% over the same quarter one year earlier. Net income for the three-month period was $349,379, up from $52,158 a year earlier. It was the company’s 14th consecutive profitable quarter.

In December 2021, Golden Matrix announced it had entered into a purchase agreement to acquire a controlling ownership interest in UK-based RKingsCompetitions Ltd., one of Ireland’s and the United Kingdom’s leading independent online competition companies. RKings presents customers with paid and free entry routes to competitions that offer a range of prizes, including residential properties, luxury and exotic motor vehicles, holiday packages, technology packages and cash. The competitions are currently open only to residents of Ireland and the United Kingdom. Golden Matrix acquired an 80% ownership interest in RKings for cash and stock. The company also secured an option to purchase the remaining 20 percent interest of RKings, subject to certain requirements.

In March 2022, Golden Matrix announced it had applied for a Mexican gaming permit and, once approved, expects to offer online gaming in Mexico as well as roll out the RKings tournament business globally.

Technology

Golden Matrix Group develops fully operational online casino turnkey solutions as well as highly modular, configurable and scalable gaming platforms for its international customers in an effort to promote user acquisition, engagement, retention and monetization. The provided white label gaming platform is unparalleled in both mobile and desktop website deployment, proving compatible throughout all major operating systems and web browsers. In addition, the platform enhances the client’s ability to cater to various gaming scenarios including but not limited to transaction management and a range of loyalty and reward programs. Moreover, user engagement is optimized through the ability to accommodate both free and paid games.

The company’s GM-X System (and recently its next generation GM-Ag System) is considered the industry standard, granting access to over 10,000 games from more than 25 game providers. Through the GM-X System, Golden Matrix offers the industry’s most extensive game portfolio. The company’s gaming partners dominate the global online gaming market to deliver innovative games and premium brand titles. The GM-X System offers payment gateways that integrate with third party platforms or digital wallets. It supports all major currencies and offers multiple language options. The system’s data analytics provide the operator with a 360-degree view of the gaming platform’s performance.

GMGI currently supports over 500 unique casino brands and over 6 million players.

Market Outlook

Online gaming and sports betting sites and apps are increasingly taking market share from traditional location-based casinos. Widespread internet service availability and increasing use of mobile phones for playing online games from homes and public places is driving the market, according to a report from Grand View Research. In addition, factors such as easy access to online gambling, legalization and cultural approval, corporate sponsorships, and celebrity endorsements are also contributing to market growth. The growing availability of cost-effective mobile applications across the globe is further expected to fuel market growth.

This trend is only expected to accelerate as millennials reach their peak earning years and Gen Z youth begin to complete their education and move into careers. These generations are completely comfortable with online recreation, and with using technology like digital wallets and digital gameplay that underpins online gaming.

The global online gambling market was valued at $53.7 billion in 2019 and is expected to grow at a CAGR of 11.5% from 2020 to 2027 to reach a value of $127.3 billion, according to Grand View Research, with much of the growth expected from the U.S. and Asia. Even Europe, the most mature gaming market, is expected to grow at a rate of 20-25% year-over-year.

Management Team

Brian Goodman is CEO of Golden Matrix Group. He has more than 20 years of diverse senior management experience and business development roles within the technology and internet gaming industries. He has a tertiary science qualification as well as a marketing and sales background. His previous roles have been entrepreneurial and include CEO and senior management positions in smaller organizations, which he founded or in which he held equity, as well as multinational organizations.

Cathy Feng is COO at Golden Matrix. She is a co-founder of GMGI and holds a Master of Commerce degree. She has 10 years of experience as a financial officer in the technology and internet gaming industries. In past management positions, she interpreted, analyzed and presented financial and operation information to facilitate business decisions, grow companies and resolve complex problems. In addition, she has skills in marketing, business development, leadership and strategic planning.

Omar Jimenez is CFO and Chief Compliance Officer at GMGI. Prior to joining the company, he was CFO and COO of Alfadan Inc., a supplier of marine outboard engines. He has held senior financial management and operational positions at public and private companies including NextPlay Technologies, American Leisure Holdings, US Installation Group and Onyx Group. He holds various accounting professional certifications, including CPA and CPCU, and degrees in finance, accounting and business.

Henry Zhang is Chief Technology Officer at Golden Matrix. He oversees all aspects of development, integration and deployment of GMGI’s technology systems. He plays a key role in evolving GMGI’s technology business to lead and shape the industry. He is responsible for developing and scaling new businesses, including online gaming, eSport and P2P Systems. He was instrumental in launching the GM-X system and has been with the company for more than six years.

Golden Matrix Group Inc. (NASDAQ: GMGI), closed Friday's trading session at $5.35, off by 2.7273%, on 55,197 volume with 758 trades. The average volume for the last 3 months is 54,835 and the stock's 52-week low/high is $3.29/$10.72.

Recent News

Lexaria Bioscience Corp. (NASDAQ: LEXX)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (NASDAQ: LEXX).

  • Lexaria Bioscience is a global innovator in drug delivery platforms, developing a technology designed to improve the performance of other medicinal products by making them more rapidly and effectively usable by patients’ bodies
  • Lexaria’s patented DehydraTECH technology has been studied in combination with a number of other products, including but not limited to, cannabidiol (“CBD”), oral nicotine, antivirals, NSAIDs, and erectile dysfunction therapies
  • The company is pursuing FDA approval under the Investigational New Drug (“IND”) process to clinically test its DehydraTECH-CBD for the treatment of high blood pressure
  • A driving focus of the company’s R&D has been to improve the speed of onset, increase bioavailability and brain absorption of active pharmaceutical ingredients

A common refrain in the world of advertising medicinal substances is that a select product can enhance a patient’s ability to live an active life despite debilitating medical conditions. Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has awarded licensing of its proprietary DehydraTECH(TM) offering for development in Japan to Premier Wellness Science Co. Ltd, a wholly owned subsidiary of Premier Anti-Aging Co. Ltd. LEXX announced that Premier is purchasing exclusive rights to DehydraTECH technology for the Japanese nonpharmaceutical market; the company will use the tech in oral liquid and nonliquid products, as well as for topical, hair-care, lip-care and cosmetics products. According to the announcement, Lexaria will receive minimum payments of $4,527,500 over the next five years, as all well as royalties from the sales of products made with DehydraTECH, which the company anticipates could be significantly greater than the minimum payments. In addition, the two companies agreed to explore the possibility of R&D collaborations. An official from Premier noted that the company partnered with Lexaria based on DehydraTECH’s superior performance and the extensive data available through Lexaria's years of testing. “Lexaria is delighted to be working with Premier Wellness Science, which we expect will dominate the newly opening Japanese market for CBD-based products," said Lexaria CEO Chris Bunka in the press release. “Premier and Lexaria share similar philosophies, such as the provision of world-leading products created through scientific advantages and placing the consumer's needs ahead of our own. We could not have found a better partner with which to introduce DehydraTECH-enabled products to the Japanese markets.” For more information, view the full press release

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company’s patented technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules.  DehydraTECH promotes fast-acting, less expensive and more effective oral drug delivery and has been thoroughly evaluated through in vivo, in vitro and human clinical testing.

DehydraTECH is covered by 21 issued and more than 50 pending patents in over 40 countries around the world. Lexaria’s first patent was issued by the U.S. Patent and Trademark Office in October 2016 (US 9,474,725 B1), providing 20 years of patent protection expiring June 2034. Multiple patents have been awarded since then and are expected in the future.

Lexaria has a collaborative research agreement with the National Research Council (NRC), the Canadian government’s premier research and technology organization. The company has filed for patent protection for specific delivery of nicotine, vitamins, NSAIDs, testosterone, estrogen, cannabinoids, terpenes, PDE5 inhibitors (with brand names like Viagra), tobacco and more.

Lexaria began developing DehydraTECH in 2014 and has since continued to strengthen and broaden the technology. The company has no plans to create or sell Lexaria-branded products containing controlled substances. Instead, Lexaria licenses its technology to other companies around the world to offer consumers the best possible performance across an array of ingestible product formats.

The company’s technology is best thought of as an additional layer that providers of consumer supplements, prescription and non-prescription drugs, nicotine and CBD products can utilize to improve the effectiveness of their own existing or planned new offerings. Lexaria has licensed DehydraTECH to multiple companies, including a world-leading tobacco producer for the research and development of smokeless, oral-based nicotine products, and for use in industries that produce cannabinoid beverages, edibles and oral products.

DehydraTECH is suitable for use with a wide range of product formats including pharmaceuticals, nutraceuticals, consumer packaged goods and over-the-counter capsules, pills, tablets and oral suspensions.

DehydraTECH Technology

Lexaria’s DehydraTECH is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients. DehydraTECH increases their effectiveness and improves the way active pharmaceutical ingredients enter the bloodstream. The major benefits to a subject ingesting a DehydraTECH-enabled drug or consumer product can be summarized by the following:

  • Speeds up delivery – the effects of the product are felt by the subject in just minutes.
  • Increases bioavailability – the technology is much more effective at delivering a drug or product into the bloodstream.
  • Increases brain absorption – animal testing suggests significant improvement in the quantity of drug delivered across the blood-brain barrier.
  • Improves drug potency – more of the ingested product is made available to the body, so lower doses are required to achieve the desired effect.
  • Reduces drug administration cost – lower doses mean lower overall drug costs.
  • Masks unwanted taste – the technology eliminates or reduces the need for sweeteners.

Lexaria has demonstrated in animal studies a propensity for DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain barrier by as much as 1,900 percent, initiating additional new patent applications and opening possibilities for improved drug delivery.

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to 10 times, reduce time of onset from one to two hours to just minutes, and mask unwanted tastes. The technology is to be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and nicotine.

Market Outlook

Lexaria’s ongoing research and development efforts are mainly focused on development of product candidates across several key segments:

  • Oral Cannabinoids – a market estimated to be worth $18.4 billion in 2021 and expected to reach $46.2 billion by 2025.
  • Antivirals – an estimated $52.1 billion market in 2021 that’s expected to grow to $66.7 billion by 2025.
  • Oral Mucosal Nicotine – smokeless tobacco products, a $13.6 billion market in 2018, is forecast to grow at 7.2 percent annually through 2025.
  • Human Hormones – estrogen and testosterone replacement therapies represented a $21.9 billion market in 2019, with a forecast CAGR of 7.7 percent through 2027.
  • Ibuprofen and Naproxen – NSAID sales totaled $15.6 billion globally in 2019 and are projected to reach $24.4 billion by 2027.
  • Vitamin D3 – the global market size was $1.1 billion in 2021, growing at 7 percent per year and expected to reach $1.7 billion in 2026.

Management Team

Chris Bunka is Chairman and CEO of Lexaria Bioscience Corp. He is a serial entrepreneur who has been involved in several private and public companies since the late 1980s. He has extensive experience in the capital markets, corporate governance, mergers and acquisitions, as well as corporate finance. He is named as an inventor on multiple patent innovations.

John Docherty, M.Sc., is the President of Lexaria. He is a pharmacologist and toxicologist, and a specialist in the development of drug delivery technologies. He is the former president and COO of Helix BioPharma Corp. (TSX: HBP). He is named as an inventor on multiple issued and pending patents.

Greg Downey is Lexaria’s CFO. He has more than 35 years of diverse financial experience in the mining, oil and gas, manufacturing, and construction industries, and in the public sector. He served for eight years as CFO for several public companies and has provided business advisory and financial accounting services to many large organizations.

Gregg Smith is a strategic advisor to Lexaria. He is a founder and private investor with Evolution VC Partners. He is a member of the Sand Hill Angels and held previous investment banking roles with Cowen and Company and Bank of America Merrill Lynch.

Dr. Philip Ainslie serves as a scientific and medical advisor to Lexaria. He is co-director for the Centre for Heart, Lung and Vascular Health, Canada. He is also Research Chair in Cerebrovascular Physiology and Professor at the School of Health and Exercise Sciences, Faculty of Health and Social Development at the University of British Columbia.

Lexaria Bioscience Corp. (LEXX), closed Friday's trading session at $2.18, off by 3.1111%, on 78,517 volume with 273 trades. The average volume for the last 3 months is 78,517 and the stock's 52-week low/high is $1.85/$12.50.

Recent News

Flora Growth Corp. (NASDAQ: FLGC)

The QualityStocks Daily Newsletter would like to spotlight Flora Growth Corp. (NASDAQ: FLGC).

According to new data released by the U.S. Department of Justice, federal arrests connected to marijuana have continued to plummet each year as states continue reforming their cannabis laws and creating markets for this substance. The report says that the number of people arrested by the U.S. Drug Enforcement Administration has registered an annual 11% decline from 2010. In that year, a total of 8,215 arrests connected to marijuana charges were made by the federal agency. However, the figure has dropped over time to the 2,576 arrests on record in 2020. It isn’t immediately clear which specific factors are behind the drop in arrests, but the DEA says the COVID-19 pandemic, which was at its peak in 2020, was responsible for a huge decline (81%) in the number of people arrested on marijuana charges between March and April 2020, when stay-at-home orders had just been issued across the country. During those two months, cannabis prosecutions also registered a 77% slump. These statistics may indirectly suggest that the marijuana consumers have come to trust the products commercialized by licensed marijuana companies such as Flora Growth Corp. (NASDAQ: FLGC) in the jurisdictions where such companies are allowed to operate.

Flora Growth Corp. (NASDAQ: FLGC) is an internationally focused cannabis brand builder that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Flora Growth operates one of the largest outdoor cultivation facilities in the world with an aim of marketing a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, the company creates premium products that help consumers restore and thrive.

Flora Growth completed the first traditional cannabis IPO on Nasdaq in May 2021. Although currently headquartered in Toronto, Ontario, with plans to relocate its head office to Miami, Florida, the company’s base of operations is in Colombia, where it has built an extensive distribution network that includes Colombia’s largest distributors.

Currently, Flora Growth is organically growing market share for its existing brand portfolio (pharmaceuticals, textiles, cosmetics, and food & beverage) while seeking revenue-generating acquisitions that offer an accretive distribution network to amplify revenue growth.

Existing Brand & Product Portfolio

Flora Growth’s portfolio spans a number of verticals – each with a thoughtful brand designed to resonate with its intended end consumer. In line with the company’s mission, each brand prioritizes natural ingredients and value-chain sustainability.

Flora Lab S.A.S

Flora Lab is the company’s GMP certified manufacturing and R&D center focused on producing pharmaceuticals, cosmetics, and nutraceuticals for domestic and international markets. Its offerings include product lines that are private label, white-label, and custom formulas.

Through Flora Lab, Flora Growth has relationships with 1,500+ distribution channels, manufactures 63+ OTC products registered with INVIMA (Colombia National Food and Drug Surveillance Institute), and holds multiple GMP certifications enabling international export in an effort to leverage Flora Lab’s capacity to produce a wide range of CBD-infused products.

Flora Beauty

Flora Beauty is the company’s CBD beauty and cosmetics division founded by fashion and beauty industry icon Paulina Vega. Its current offerings include two CBD skincare brands targeting the U.S. and Latin American markets – MIND NATURALS and AWE. These lines exemplify Flora Growth’s socially conscious approach to business.

Currently, Flora Beauty products are offered globally through e-commerce, as well as through Falabella’s 111 retail locations across Latin America. The company is in negotiations with major department stores to launch the line in the U.S. and is also exploring opportunities in the U.K. and other European markets.

KASA Wholefoods

KASA Wholefoods is a Colombian manufacturer of food and beverages leveraging responsibly sourced exotic fruits from the Amazon. KASA has a $10 million+ distribution agreement with Tropi, Colombia’s largest food distributor, which has 130,000+ distribution points across the country.

Mambe, KASA’s leading brand, is already offered through over 980 distribution points across Colombia. Flora Growth expects this network to grow to over 1,200 distribution points in 2021, including one of Colombia’s largest coffee chains, Tostao Café & Pan.

Hemp Textiles & Co.

Through its Hemp Textiles division, Flora Growth intends to utilize its large land package and cultivation infrastructure to capture market share in the rapidly growing hemp industrials segment.

The company’s first brand through this division, Stardog Loungewear, offers a line of comfortable loungewear made from natural, organic materials. Stardog has been distributing globally through e-commerce and brick and mortar channels in Bogota since fall 2020, and the company intends to open U.S. brick and mortar locations in 2021.

Accretive M&A

Flora Growth is targeting transactions to complete the supply chain via key infrastructure to enhance its global distribution with the aim to compete on low-cost, high-quality inputs paired with premium brands that create business lines with robust margins.

To date, Flora has announced two major transactions.

Koch & Gsell (Acquisition)

  • Amplify CPG portfolio’s revenue growth through leading brand, Heimat, currently with TTM revenues of $7.6 million.
  • Leverage Koch &Gsell’s distribution network of 2,500+ stores to introduce Flora to the Swiss, European and Asian markets.
  • Bring patented hemp cigarette manufacturing technology into new markets utilizing Flora’s high-quality cannabis.

Hoshi International (Investment)

  • Equity Investment of €2 million into Hoshi to establish Flora as a preferred supplier to two EU processing facilities.
  • Opens gateway for Flora Growth’s cannabis through international distribution agreements in the EU and U.K.
  • Hoshi’s experienced team and increased access to the EU cannabis market to serve as a catalyst for revenue growth.

Cultivation

Key to Flora Growth’s expansion efforts is its cultivation strategy. The company’s Cosechemos farm, located in Bucaramanga, Colombia, is currently licensed to cultivate 247 acres of cannabis. Through three successful pilot crop plantings, the location has demonstrated a production cost of just $0.06/gram. For comparison, the average cost of North American cannabis (based on 2019 figures from Aphria, Tilray, Sundial, and Aurora) equates to roughly $1.89/gram.
Flora Growth is uniquely positioned to capitalize on Colombia’s favorable growing conditions, low-cost infrastructure, and affordable local workforce as it looks to ramp up its cultivation efforts moving forward.

Leadership Team

Bernard Wilson is the Chairman of Flora Growth. A senior financial professional, Dr. Wilson is the former Vice-Chairman of PricewaterhouseCoopers LLP and is the Chairman of the Founders Board of the Institute of Corporate Directors. He has also served as Chairman of the Canadian Chamber of Commerce; Chairman of the International Chamber of Commerce – Canada; and Member of the Canada/U.S. Trade Committee. Dr. Wilson draws on this experience to ensure Flora Growth adheres to effective corporate governance practices.

Luis Merchan is the company’s President and CEO. He is a proven executive with over a decade of experience in enterprise sales management, corporate strategy, merchandising and expense management, and customer experience. Mr. Merchan previously served as Macy’s Inc.’s Vice President of Workforce Strategy and Operations, where he managed the enterprise’s multi-billion-dollar P&L expense line for the entire 540 store portfolio. Throughout his tenure at Macy’s, he led various sales and marketing initiatives, including the B2B corporate sales team that was responsible for $160 million in annual revenue. Mr. Merchan obtained his Bachelor of Industrial Engineering from Pontifical Xaverian University in Bogota, Colombia, and his MBA from McNeese State University. He also holds a Graduate Certificate in Marketing Management from Harvard.

Juan Manuel Galan is a Strategic Advisor to the Flora Growth management team. Mr. Galan currently serves as a senior consultant to The World Bank. He is a politician and former senator of Colombia, serving three terms from 2006 to 2018 as a member of the Colombian Liberal Party. He is also a former professor at the University of Rosario and holds more than 20 years of journalistic, academic, governmental and parliamentary experience. During his time as a senator, Mr. Galan was a key leader, with 29 bills and 27 debates on political control, and 17 laws to his name. The most relevant of those laws was authoring the medical cannabis law that resulted in the legalization of medical cannabis in Colombia.

Stan Bharti is a Director of Flora Growth. Mr. Bharti currently serves as Executive Chairman of Forbes & Manhattan. He has more than 30 years of professional experience in business, finance, markets, operations and more, with a focus on the resource and technology sectors. To date, Mr. Bharti has amassed over $3 billion worth of investment capital for the companies with which he has worked and their shareholders. He is a Professional Mining Engineer and holds a master’s degree in engineering from Moscow, Russia, and University of London, England.

Javier Franco is the company’s VP of Agriculture. Mr. Franco is a master horticulturist with more than 25 years of experience in the design, implementation, and management of cultivation and propagation facilities of more than 30 species of cut flowers in Latin America. He completed his agricultural studies at Zamorano University in Honduras and later at an International Exchange Program at Ohio State University. Mr. Franco has directed technical, commercial, and research groups in the cut flower, fruit and vegetable markets in Latin America and has participated in the commercial development of new technologies applied in agribusiness. He has also led the agri-management of organic crops and certifications of Good Agricultural Practices.

Flora Growth Corp. (FLGC), closed Friday's trading session at $0.892, off by 5.1064%, on 685,335 volume with 1,398 trades. The average volume for the last 3 months is 684,526 and the stock's 52-week low/high is $0.88/$21.45.

Recent News

Home Bistro Inc. (OTC: HBIS)

The QualityStocks Daily Newsletter would like to spotlight Home Bistro Inc. (OTC: HBIS).

Home Bistro (OTC: HBIS), a Miami-based online meal delivery platform that offers celebrity chef-inspired, gourmet and lifestyle ready-made meals, is distinguishing itself as a leader in the burgeoning meal kit delivery market. “Home Bistro has taken the basic idea of home delivery meals and elevated it – every direct-to-consumer, heat-to-eat gourmet meal the company offers on its tempting and tasty online menu is inspired by a renowned executive or celebrity chef. The list of chefs who have partnered with the company is impressive and includes Cat Cora, owner of more than 18 restaurants, bestselling cookbook author Daina Falk… and Claudia Sandoval, winner of the sixth season of ‘MasterChef U.S.’ Others who have created menu offerings include Richard Blais, winner of ‘Top Chef All-Stars,’ and Ayesha Curry, a bestselling author, restauranteur and television host,” a recent article reads. “Home Bistro’s approach of collaborating closely with renowned chefs is clearly working. Earlier this year, the company reported record first-quarter revenue, with sales for Q1 2022 up 101% to $802,000; that increase, in part, was attributed to growing product sales of celebrity chefs Cat Cora and Diana Falk, as well as the mid-quarter launch of Claudia Sandoval and Richard Blais product offerings.” To view the full article, visit https://ibn.fm/imEvk

Home Bistro Inc. (OTC: HBIS) is a Miami-based company engaged in the business of providing prepackaged and prepared meals to consumers. The company has created the next generation of prepared meal delivery – Ready-Made Gourmet Meal Delivery 3.0.

Home Bistro addresses the three major problems facing the prepared food delivery market: poor food quality; customers tired of eating the same meals; and, eating at home is still eating at home, with the accompanying food preparation and clean up chores. The company addresses these problems by delivering high quality food fresh and fast, providing customers a variety of meal choices from a diverse lineup of celebrity chefs, and requiring simple prep and easy clean up without sacrificing the fine dining experience.

Home Bistro offers a family of high quality, direct-to-consumer, ready-made, gourmet meals. Using the latest fresh food “skin-packing” technology, Home Bistro offers a virtual “Bistro Emporium” where consumers can cross select from a wide variety of siloed “bistros,” each with a dedicated section and unique visitor experience created by a renowned celebrity/executive chef. Meals delivered fresh can be eaten within 10 to 14 days or frozen for up to six months.

The company’s mission is to lead the next generation of heat-to-eat food delivery with unique and delicious cuisine and an experience that excites the market. Home Bistro’s advantage in the highly competitive meal delivery space is meal diversity – with the best celebrity chefs from around the world, offering a home-based fine dining experience through a selection of over 50 unique gourmet meals, as well as offering a developing selection of desserts and single-serving wine to perfectly complement the meal experience. In addition, the company uses only the highest quality ingredients in its meals and preserves their freshness by employing state-of-the-art vacuum skin packing.

In mid-2021, Home Bistro acquired southern-California based Model Meals, a lifestyle ready-to-eat meal prep service, which is Whole30 and Paleo approved, while then only serving three states. In September 2021, Home Bistro commenced shipping Model Meals to all 50 states and recently announced that it will launch a subscription-based service for Model Meals consisting of three meals per day (breakfast, lunch and dinner) for up to five days per week. The subscription service, expected to launch by May 2022, will initially target the Southern California market, where Model Meals maintains a food production and fulfillment facility and enjoys a strong customer base.

Brands and Products

Home Bistro’s leading online platform (www.homebistro.com) provides direct-to-consumer, heat-to-eat, celebrity chef-inspired gourmet meals. Offerings currently include inspirations developed by “Iron Chef” Cat Cora, two-time New York Times best-selling cookbook author and TV host Ayesha Curry, sports-tailgating focused creator of “Hungry Fan” Chef Diana Falk, “Master Chef” Claudia Sandoval, and “Top-Chef All-Star” Richard Blais. Soon-to-launch celebrity chefs on the Home Bistro platform include “Caterer to the Stars” Roblé Ali, “zero-waste cooking” celebrity chef Priyanka Naik, and CHOPPED champion Melanie Moss.

Home Bistro’s Model Meals lifestyle brand (www.modelmeals.com) is a Whole30 and Paleo approved, ready-to-eat meal prep service, offering a weekly rotating menu that is prepared by professional chefs, using only the highest quality ingredients available, sourced responsibly and locally, and delivered in sustainable, eco-friendly packaging.
Home Bistro has partnered with celebrity chef Melanie Moss to expand its dessert menu options. In keeping with its mission to deliver a complete gourmet culinary experience to discerning customers, Home Bistro beta-tested its first dessert – a delicious, sweet and salty caramel brownie. Based on the encouraging results, the company is moving forward to create a much more robust dessert menu.

Home Bistro has formally launched its wine offering initiative with In Good Taste Wines, a unique direct-to-consumer wine platform that empowers wine lovers to “discover the world, by the glass.” The company has worked diligently with the In Good Taste Wines team to develop a unique selection of elegant single-serving wines to pair with Home Bistro’s celebrity chef-inspired meals. The partnership with In Good Taste Wines provides Home Bistro with a low-cost, incremental source of revenue, which will assist the company in expanding its gross profit margin and lead it to faster profitability.

Market Outlook

Global revenue in the online food delivery sector was $136 billion in 2020 and forecast to grow steadily at a 7.5% CAGR through 2024 to a projected value of $182 billion.
In the U.S., the food delivery sector, which comprises both the restaurant-to-consumer segment and the platform-to-consumer segment where Home Bistro operates, is expected to surpass $32.3 billion in 2024. The company’s addressable market, the platform-to-consumer segment, is approximately 30% of the U.S. market and is projected to reach a value of $9.7 billion by 2024. This segment is expected to grow even faster than the sector as a whole as providers refine their focus on healthier meals, more convenient delivery and subscription options and more advanced meal processing technology.

Management Team

Zalmi Duchman is Chairman and CEO at Home Bistro. He was CEO and founder of The Fresh Diet online meal delivery service, which grew from a startup to over $30 million in annual revenue. He is a thought leader, investor and publisher of numerous articles in the food tech sector. He was named one of Forbes “America’s Most Promising CEOs Under 35,” and was named a Miami Herald “20 Under 40” entrepreneur in 2014.

Carlo Ricci is Director of Operations at Home Bistro. He was VP Operations for The Fresh Diet online meal delivery service, where he developed the culinary and R&D departments and established distribution centers in five states. He was also Operations Manager at Homemade Meals, where he developed and implemented inventory systems, established production facilities on both coasts and trained and managed personnel. He has a bachelor’s degree in data analytics from Miami Dade College.

Camille May is CFO at Home Bistro. She is a co-founder of Model Meals meal delivery service, where she has served as CFO since the company’s inception in 2015. She helped build the company from the ground up to more than $2 million in annual revenue. Prior to Model Meals, she worked as a financial analyst and broker in commercial real estate. She has a BBA in finance from the Leeds School of Business at the University of Colorado.

Danika Brysha is Chief Marketing Officer at Home Bistro. She co-founded Model Meals and was also a co-founder of the Self-Care Society. She is a former fashion model and founder of Danika Brysha Inc., a service specializing in modeling, coaching, speaking, events, media and influence. She is creator of the Brunch Series and a Whole30 certified coach. She is also host of the top-rated podcast “Light + Life Live” and is a lifestyle design expert. She earned a bachelor’s degree from the University of Colorado.

Home Bistro Inc. (OTC: HBIS), closed Friday's trading session at $0.45, off by 0.066622%, on 3,191 volume with 3 trades. The average volume for the last 3 months is 3,191 and the stock's 52-week low/high is $0.15/$1.98.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.